Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of TS-142 (vornorexant) in Healthy Japanese Male Subjects
jRCT2071220103Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vornorexant in Insomnia, sponsored by Taisho Pharmaceutical. Primary endpoint: Plasma concentration of unchanged form and its metabolites. Started Feb 2023; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT2071220103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220103.